Literature DB >> 24383551

Circulating endothelial progenitor cells as a predictor of response to cardiac resynchronization therapy: the missing piece of the puzzle?

Natália António1, Ana Soares, Tiago Carvalheiro, Rosa Fernandes, Artur Paiva, Miguel Ventura, João Cristóvão, Luís Elvas, Lino Gonçalves, Luís A Providência, Carlos Fontes Ribeiro, Guilherme Mariano Pego.   

Abstract

BACKGROUND: It would be important to better identify heart failure (HF) patients most likely to respond to cardiac resynchronization therapy (CRT). Because endothelial progenitor cells (EPCs) play a crucial role in the maintenance of vascular endothelium integrity, we hypothesize that patients who have higher circulating EPCs levels have greater neovascularization potential and are more prone to be responders to CRT.
METHODS: Prospective study of 30 consecutive patients, scheduled for CRT. Echocardiographic evaluation was performed before implant and 6 months after. Responders to CRT were defined as patients who were still alive, have not been hospitalized for HF management, and demonstrated ≥15% reduction in left ventricular end-systolic volume (LVESV) at the 6-month follow-up. EPCs were quantified before CRT, from peripheral blood, by flow cytometry using five different conjugated antibodies: anti-CD34, anti-KDR, anti-CD133, anti-CD45, and anti-CXCR4. We quantified five different populations of angiogenic cells: CD133(+) /CD34(+) cells, CD133(+) /KDR(+) cells, CD133(+) /CD34(+) /KDR(+) cells, CD45(dim) CD34(+) /KDR(+) cells, and CD45(dim) CD34(+) /KDR(+) /CXCR4(+) cells.
RESULTS: The proportion of responders to CRT at the 6-month follow-up was 46.7%. Responders to CRT presented higher baseline EPCs levels than nonresponders (0.0003 ± 0.0006% vs 0.0001 ± 0.0002%, P = 0.04, for CD34(+) /CD133(+) /KDR(+) and 0.0006 ± 0.0005% vs 0.0003 ± 0.0003%, P = 0.009, for CD45(dim) CD34(+) /KDR(+) /CXCR4(+) cells). In addition, baseline levels of CD45(dim) CD34(+) /KDR(+) /CXCR4(+) cells were positively correlated with the reduction of LVESV verified 6 months after CRT (r = 0.497, P = 0.008).
CONCLUSIONS: High circulating EPCs levels may identify the subset of HF patients who are more likely to undergo reverse remodeling and benefit from CRT. Addition of EPCs levels assessment to current selection criteria may improve the ability to predict CRT response. ©2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiac resynchronization therapy; endothelial progenitor cells; responders

Mesh:

Year:  2014        PMID: 24383551     DOI: 10.1111/pace.12334

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  6 in total

1.  Impact of prior chronic statin therapy and high-intensity statin therapy at discharge on circulating endothelial progenitor cell levels in patients with acute myocardial infarction: a prospective observational study.

Authors:  Natália António; Rosa Fernandes; Ana Soares; Francisco Soares; Ana Lopes; Tiago Carvalheiro; Artur Paiva; Guilherme Mariano Pêgo; Luís A Providência; Lino Gonçalves; Carlos Fontes Ribeiro
Journal:  Eur J Clin Pharmacol       Date:  2014-07-22       Impact factor: 2.953

2.  Hypersplenism: an independent risk factor for myocardial remodeling in chronic heart failure patients.

Authors:  Yong Tang; Wenbin Lu; Ziwei Zhang; Pengfei Zuo; Genshan Ma
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 3.  Cellular and Molecular Aspects of Dyssynchrony and Resynchronization.

Authors:  Jonathan A Kirk; David A Kass
Journal:  Card Electrophysiol Clin       Date:  2015-12

4.  Pattern of endothelial progenitor cells and apoptotic endothelial cell-derived microparticles in chronic heart failure patients with preserved and reduced left ventricular ejection fraction.

Authors:  Alexander E Berezin; Alexander A Kremzer; Yulia V Martovitskaya; Tatyana A Berezina; Elena A Gromenko
Journal:  EBioMedicine       Date:  2016-01-20       Impact factor: 8.143

5.  Improvement in circulating endothelial progenitor cells pool after cardiac resynchronization therapy: increasing the list of benefits.

Authors:  Gonçalo Cristóvão; James Milner; Pedro Sousa; Miguel Ventura; João Cristóvão; Luís Elvas; Artur Paiva; Lino Gonçalves; Carlos Fontes Ribeiro; Natália António
Journal:  Stem Cell Res Ther       Date:  2020-05-24       Impact factor: 6.832

Review 6.  Usefulness of Biomarkers for Predicting Response to Cardiac Resynchronization Therapy.

Authors:  Mohammad H Asgardoon; Ali Vasheghani-Farahani; Alborz Sherafati
Journal:  Curr Cardiol Rev       Date:  2020
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.